Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new collaborative study from the Oxford Parkinson’s Disease Centre has revealed that GABA transporters on astrocytes, the brain's lesser known yet critically important cells, support dopamine release and are sites of early dysfunction in parkinsonism.

Showing striatal immunofluorescence signals for astrocyte marker S100β and neuronal marker NeuN
Striatal immunofluorescence signals for astrocyte marker S100β (magenta) and neuronal marker NeuN (yellow)

The release of the neurotransmitter dopamine in the brain region called the striatum plays key roles in both our motivation and how we select our actions. This release is dysregulated across diverse disorders including Parkinson's and various addictions. Unravelling the mechanisms by which dopamine release in the striatum is governed, and understanding how these mechanisms might be dysfunctional in disease, is critical for identifying novel targets for disease-modifying therapies.

A new study funded by Parkinson's UK and published in Nature Communications, led by Department of Physiology, Anatomy & Genetic's Professor Stephanie Cragg and Dr Bradley Roberts, and in collaboration with the Oxford Parkinson’s Disease Centre, uncovers new observations about how non-neuronal cells in the brain, namely astrocytes, regulate striatal dopamine release and are sites of early dysfunction in Parkinson’s.

The full story is available on the Department of Physiology, Anatomy & Genetics website

 

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.